NRx Pharmaceuticals Inc (NASDAQ:NRXPW) — Market Cap & Net Worth
Market Cap & Net Worth: NRx Pharmaceuticals Inc (NRXPW)
NRx Pharmaceuticals Inc (NASDAQ:NRXPW) has a market capitalization of $123.23 ($123.23) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31482 globally and #6056 in its home market, demonstrating a 76.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NRx Pharmaceuticals Inc's stock price $0.01 by its total outstanding shares 9858 (9.86K). Analyse NRx Pharmaceuticals Inc cash conversion from operations to see how efficiently the company converts income to cash.
NRx Pharmaceuticals Inc Market Cap History: 2017 to 2026
NRx Pharmaceuticals Inc's market capitalization history from 2017 to 2026. Data shows change from $3.94K to $123.22 (-32.73% CAGR).
NRx Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NRx Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
NRx Pharmaceuticals Inc's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $3.79K | $1.09 Million | $66.10K | 0.00x | 0.06x |
| 2019 | $1.71K | $1.21 Million | $408.43K | 0.00x | 0.00x |
| 2025 | $697.95 | $1.23 Million | -$28.62 Million | 0.00x | N/A |
Competitor Companies of NRXPW by Market Capitalization
Companies near NRx Pharmaceuticals Inc in the global market cap rankings as of May 4, 2026.
Key companies related to NRx Pharmaceuticals Inc by market ranking:
- VIFRANA (RO:BIOW): Ranked #31473 globally with a market cap of $186.44 USD ( RON811.96 RON).
- Ordinary Fully Paid Deferred Settlement (AU:ADDDB): Ranked #31474 globally with a market cap of $182.95 USD ( AU$258.57 AUD).
- Us1 Critical Minerals Limited (AU:USC): Ranked #31483 globally with a market cap of $120.96 USD ( AU$170.95 AUD).
- Peak Processing Limited (AU:PKP): Ranked #31484 globally with a market cap of $119.66 USD ( AU$169.11 AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #31473 | VIFRANA | RO:BIOW | $186.44 | RON0.08 |
| #31474 | Ordinary Fully Paid Deferred Settlement | AU:ADDDB | $182.95 | AU$0.03 |
| #31483 | Us1 Critical Minerals Limited | AU:USC | $120.96 | AU$0.02 |
| #31484 | Peak Processing Limited | AU:PKP | $119.66 | AU$0.02 |
NRx Pharmaceuticals Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, NRx Pharmaceuticals Inc's market cap moved from $3.94K to $ 123.22, with a yearly change of -32.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $123.22 | -82.34% |
| 2025 | $697.95 | -44.69% |
| 2024 | $1.26K | -1.31% |
| 2023 | $1.28K | -48.14% |
| 2022 | $2.47K | -86.48% |
| 2021 | $18.24K | -60.64% |
| 2020 | $46.33K | +2608.93% |
| 2019 | $1.71K | -54.85% |
| 2018 | $3.79K | -3.92% |
| 2017 | $3.94K | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of NRx Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $123.23 USD |
| MoneyControl | $123.23 USD |
| MarketWatch | $123.23 USD |
| marketcap.company | $123.23 USD |
| Reuters | $123.23 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NRx Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in p… Read more